Retreating patients with hepatitis C: Telaprevir boosts cure rate

Adding the investigational drug telaprevir to standard treatment for hepatitis C infection cures about half the patients willing to give therapy a second try. That compares to a cure rate of just 14 percent among those who were retreated with the standard regimen, according to researchers at the Duke Clinical Research Institute (DCRI).

Read the whole article on Physorg

More from Physorg